EUVIMEDEUVIMED entdecken
Open Access

CASTOR1 functional inactivation drives KRAS -mutant NSCLC and therapy resistance by a noncanonical mechanism of tumor suppression

Xian Wang iD, Ling Ding iD, Wen Meng iD, Elaine Byrnes, Suet Kee Loo iD, Shenyu Sun, Luping Chen, Tingting Li, Man-Tzu Wang iD, Arjun Pennathur iD, Yufei Huang iD, Shou-Jiang Gao iD

Science Advances · 2026

DOI: 10.1126/sciadv.aeb9836 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Xian Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Virology Center, UPMC Hillman Cancer Center, Pittsburgh, PA 15213, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Proto-Oncogene Proteins p21(ras), Lung Neoplasms, Drug Resistance, Neoplasm. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CASTOR1, a cytosolic arginine sensor and regulator of mTORC1 signaling, is identified here as a tumor suppressor in KRAS -driven non–small cell lung cancer (NSCLC). In a KRAS G12D mouse model, CASTOR1 deletion enhances tumor initiation and progression, accompanied by increased proliferation. Although CASTOR1 is rarely mutated or deleted in human cancers, its expression progressively declines during tumor progression and is associated with increased AKT activation and CASTOR1 phosphorylation, consistent with functional inactivation. Loss of CASTOR1 results in constitutive mTORC1 hyperactivation, impaired arginine-dependent regulation of mTORC1 signaling, elevated p-4EBP1 and p-S6 levels, increased AKT and ERK activation, genomic instability, and resistance to KRAS G12D inhibitors. Tumors and tumor-derived organoids deficient in CASTOR1 are resistant to KRAS inhibition, but this resistance can be overcome by cotargeting mTORC1 or dual PI3K/mTOR inhibition. These findings identify CASTOR1 as a critical link between nutrient sensing and oncogenic signaling and reveal its functional inactivation as an important mechanism contributing to KRAS -driven NSCLC progression and therapeutic resistance. The results further support rational combination therapies to overcome KRAS inhibitor resistance in CASTOR1-low NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungProto-Oncogene Proteins p21(ras)Lung NeoplasmsDrug Resistance, NeoplasmMutationAnimalsHumansMiceMechanistic Target of Rapamycin Complex 1Signal TransductionCell Line, TumorProto-Oncogene Proteins c-aktIntracellular Signaling Peptides and Proteins

Substanzen

Proto-Oncogene Proteins p21(ras)Mechanistic Target of Rapamycin Complex 1CASTOR1 protein, humanProto-Oncogene Proteins c-aktKRAS protein, humanIntracellular Signaling Peptides and Proteins

Autor:innen und Institutionen

  • Cancer Virology Center, UPMC Hillman Cancer Center, Pittsburgh, PA 15213, USA.
  • Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
  • Department of Cardiothoracic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
  • Cancer Biology Program, UPMC Hillman Cancer Center, Pittsburgh, PA 15213, USA.
  • Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.

ORCID-Profile: Xian Wang, Ling Ding, Wen Meng, Suet Kee Loo, Man-Tzu Wang, Arjun Pennathur, Yufei Huang, Shou-Jiang Gao

Förderung

  • NCI NIH HHS
  • National Institutes of Health

Zitieren

APA

Wang, X., Ding, L., Meng, W., Byrnes, E., Loo, S. K., Sun, S., Chen, L., Li, T., Wang, M. T., Pennathur, A., Huang, Y., & Gao, S. J. (2026). CASTOR1 functional inactivation drives KRAS -mutant NSCLC and therapy resistance by a noncanonical mechanism of tumor suppression. Science Advances. https://doi.org/10.1126/sciadv.aeb9836

Vancouver

Wang X, Ding L, Meng W, Byrnes E, Loo SK, Sun S, et al. CASTOR1 functional inactivation drives KRAS -mutant NSCLC and therapy resistance by a noncanonical mechanism of tumor suppression. Science Advances. 2026. doi:10.1126/sciadv.aeb9836

BibTeX
@article{Wang2026,
  author = {Wang, Xian and Ding, Ling and Meng, Wen and Byrnes, Elaine and Loo, Suet Kee and Sun, Shenyu and Chen, Luping and Li, Tingting and Wang, Man-Tzu and Pennathur, Arjun and Huang, Yufei and Gao, Shou-Jiang},
  title = {CASTOR1 functional inactivation drives KRAS -mutant NSCLC and therapy resistance by a noncanonical mechanism of tumor suppression},
  journal = {Science Advances},
  year = {2026},
  doi = {10.1126/sciadv.aeb9836}
}
Kostenlos starten →